(Q38408716)

English

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

scientific article published on 03 July 2015

In more languages

Statements

scholarly article

1 reference

2 September 2017

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). (English)

1 reference

2 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

C Zhou

1

1 reference

2 September 2017

Y L Wu

2

1 reference

2 September 2017

G Chen

3

1 reference

2 September 2017

J Feng

4

1 reference

2 September 2017

X-Q Liu

5

1 reference

2 September 2017

C Wang

6

1 reference

2 September 2017

S Zhang

7

1 reference

2 September 2017

J Wang

8

1 reference

2 September 2017

S Zhou

9

1 reference

2 September 2017

S Ren

10

1 reference

2 September 2017

S Lu

11

1 reference

2 September 2017

L Zhang

12

1 reference

2 September 2017

C Hu

13

1 reference

2 September 2017

C Hu

14

1 reference

2 September 2017

Y Luo

15

1 reference

2 September 2017

L Chen

16

1 reference

2 September 2017

M Ye

17

1 reference

2 September 2017

J Huang

18

1 reference

2 September 2017

X Zhi

19

1 reference

2 September 2017

Y Zhang

20

1 reference

2 September 2017

Q Xiu

21

1 reference

2 September 2017

J Ma

22

1 reference

2 September 2017

L Zhang

23

1 reference

2 September 2017

C You

24

1 reference

2 September 2017

publication date

3 July 2015

1 reference

2 September 2017

Annals of Oncology

1 reference

2 September 2017

26

1 reference

2 September 2017

1877-1883

1 reference

2 September 2017

9

1 reference

2 September 2017

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV276

21 January 2018

Identifiers

10.1093/ANNONC/MDV276

1 reference

2 September 2017

1 reference

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38408716&oldid=1523835269"